Clinical Trial: Gemcitabine Plus Nab-paclitaxel As Switch Maintenance Versus Continuation of Modified FOLFIRINOX As 1st Line Chemotherapy in Patients with Advanced Pancreatic Cancer.

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06897644) titled 'Gemcitabine Plus Nab-paclitaxel As Switch Maintenance Versus Continuation of Modified FOLFIRINOX As 1st Line Chemotherapy in Patients with Advanced Pancreatic Cancer.' on March 20.

Brief Summary: PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Pancrea...